AOTI Inc. today announced that a state-of-the-art Randomized Controlled Trial (RCT) demonstrating the efficacy of its unique multi-modality cyclical pressure Topical Wound Oxygen (TWO2) therapy in healing and reducing recurrence of Diabetic Foot Ulcers (DFU) has been published online ahead of print in Diabetes Care (2019;42:1–9), the leading multi-disciplinary peer reviewed journal for health care […]
OCEANSIDE, Calif., June 19, 2019 /PRNewswire/ — AOTI Inc. today announced that it has been awarded a new five-year Federal Supply Schedule (FSS) contract for its patented Topical Wound Oxygen (TWO2) therapy by the National Acquisition Center, U.S. Department of Veterans Affairs (VA). Under delegated authority by the General Services Administration (GSA), the VA Federal Supply Schedule (FSS) program supports […]
It is clear there is a growing tsunami of interest in our products and their unprecedented complete healing benefits. We expect and hope that as our latest state-of-the-art Randomized Controlled Trial (RCT) is published that TWO2therapy will be made available to all chronic wound patients worldwide.
OCEANSIDE, Calif., Jan. 18, 2019 /PRNewswire/ — AOTI Inc. announced today that it has entered into a major strategic relationship with a leading Chinese medical company, Nanning Xinzizhu Trading Co.,Ltd, for distribution of its patented Topical Wound Oxygen (TWO2) therapy wound healing products into the People’s Republic of China. The multi-year agreement includes minimum sales performance expectations totaling close to $18 million. […]
OCEANSIDE, Calif., Oct. 18, 2018 /PRNewswire/ — AOTI Inc. announced today that it will participate at Jefferies 2018 London Healthcare Conference, being held on November 14 and 15, 2018 in London, United Kingdom. Now in its ninth year, the Jefferies conference is the largest healthcare-dedicated conference in Europe, hosting over 400 participating companies, 1,800 attendees and 4,500 business-to-business and investor meetings. The event will […]
OCEANSIDE, Calif., Oct. 11, 2018 /PRNewswire/ — AOTI Inc. announced today that expanded results from its recently concluded Randomized Controlled Trial (RCT) demonstrating the efficacy of its patented multi-modality Topical Wound Oxygen (TWO2) homecare therapy in healing Diabetic Foot Ulcers, has been chosen as one of the three best poster abstracts at the leading DFCon – Diabetic Foot Global […]
We are delighted to invest in this new facility that will allow us to more effectively ramp up production of our unique multi-modality wound care therapy product line to meet our continually expanding supply needs,” stated Dr. Mike Griffiths, Chief Executive Officer and President of AOTI.
This breakthrough study unequivocally demonstrates at the highest scientific level the efficacy of Cyclical Pressure Topical Wound Oxygen Therapy in healing Diabetic Foot Ulcers” stated Dr. Robert Frykberg, the Chief Principle Investigator of the study.
The study was a two-year retrospective review of 71 patients with a total of 115 wounds treated by a Veterans Affairs hospital in Chicago that prescribed cyclical pressurized TWO2 therapy for use at home.
AOTI Inc. announced today that its fully owned USA-operating subsidiary, Advanced Oxygen Therapy Inc., has recently opened a New York City Office in Yonkers, New York to support the ever-increasing usage of its unique Topical Wound Oxygen (TWO2) homecare therapy. This new East Coast location has also been approved by the Accreditation Commission for Health Care (ACHC) under the company’s DMEPOS accreditation for Home/Durable Medical Equipment Services.